Table I.
Clinicopathological features at presentation according to the subtype of PTC.
| Variable | TCV of PTC (n=16) | CaFVs of PTC (n=34) | P-value | |
|---|---|---|---|---|
| Female gender (%) | 11 (68.8) | 28 (82.4) | 0.400 | |
| Age, years (SD) | 57 (18.5) | 50.8 (15.7) | 0.100 | |
| Follow-up time, months (%) | 15 (93.8) | 34 (100.0) | 0.100 | |
| Type of surgery, n (%) | 0.100 | |||
| obectomy | 1 (6.2) | 1 (2.9) | ||
| Subtotal thyroidectomy | 2 (12.5) | 0 (0.0) | ||
| Total thyroidectomy | 13 (81.3) | 33 (97.1) | ||
| Lymphadenectomy | 5 (31.3) | 9 (26.4) | 0.900 | |
| Surgical re-intervention, n (%) | 2 (12.5) | 2 (5.9) | 0.800 | |
| Received RAI treatment, n (%) | 15 (93.8) | 33 (97.1) | 0.500 | |
| Tumor size, cm (SD) | 2.1 (0.9) | 2.6 (1.7) | 0.600 | |
| Multifocal tumor, n (%) | 8 (50.0) | 9 (26.4) | 0.090 | |
| Bilateral tumor, n (%) | 5 (31.3) | 5 (14.7) | 0.200 | |
| Positive margin status, n (%) | 13 (81.3) | 24 (70.6) | 0.300 | |
| Lymphovascular invasion, n (%) | 6 (37.5) | 10 (29.4) | 0.500 | |
| Perineural invasion, n (%) | 0 (0.0) | 1 (2.9) | 1.000 | |
| Extrathyroid extension, n (%) | 9 (56.3) | 5 (14.7) | 0.007b | |
| Lymph node metastases, n (%) | 9 (56.3) | 9 (26.4) | 0.040b | |
| Distant metastases, n (%) | 1 (6.2) | 0 (0.0) | 0.300 | |
| TNM staging, n (%)a | 0.010b | |||
| I | 5 (31.3) | 19 (55.9) | ||
| II | 1 (6.2) | 8 (23.5) | ||
| III | 2 (12.5) | 6 (17.6) | ||
| IV | 8 (50.0) | 1 (2.9) | ||
| Tumor stage III/IV, n (%) | 10 (62.5) | 7 (20.5) | 0.009b |
a
TNM staging was performed according to the criteria of Edge et al (17).
b
Significant values (P≤0.05). TCV, tall cell variant; PTC, papillary thyroid carcinoma; CaFVs, classical and follicular variants; RAI, radioactive iodine; SD, standard deviation; TNM, tumor-node-metastasis.